Clinical Research Papers:
Perioperative entecavir for patients with HBV-related hepatocellular carcinoma and low levels of viral DNA: analysis using propensity score matching
Metrics: PDF 634 views | HTML 1115 views | ?
Bao-Hong Yuan1,*, Ru-Hong Li1,*, Wei-Ping Yuan2,*, Bang-De Xiang2,*, Ming-Hua Zheng3, Tian Yang4, Jian-Hong Zhong2 and Le-Qun Li2
1 Department of General Surgery, Yan’An Hospital Affiliated to Kunming Medical University, Kunming, China
2 Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China
3 Department of Hepatology, Liver Research Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
4 Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China
* These authors have contributed equally to this work
Jian-Hong Zhong, email:
Tian Yang, email:
Keywords: hepatocellular carcinoma, Hepatitis B virus, entecavir, HBV reactivation, liver function
Received: January 09, 2017 Accepted: January 27, 2017 Published: February 16, 2017
The safety and efficacy of perioperative antiviral therapy for patients with hepatitis B virus related hepatocellular carcinoma and low serum levels of hepatitis B virus DNA are unknown. This retrospective study compared serum levels of hepatitis B virus DNA, liver function, morbidity, and length of hospital stay between patients who underwent hepatic resection alone and patients who received entecavir therapy before and after resection (n = 44 in each group). Propensity score matching was used to reduce confounding due to baseline differences between the groups. Hepatitis B virus reactivation during follow-up, which lasted a median of 6.1 months, occurred in one patient in the entecavir group (2.3%) and 11 patients in the resection-only group (25%; P = 0.02). Liver function, especially alanine aminotransferase levels, recovered much faster in the entecavir group. This group also showed a slightly lower rate of morbidity (P = 0.081) as well as significantly shorter overall hospital stay (20.1 ± 4.9 vs 24.9 ± 13.2 days; P = 0.028) and postoperative hospital stay (11.4 ± 1.9 vs 16.8 ± 13.1 days; P = 0.008). These results from this pilot study suggest that patients with hepatitis B virus related hepatocellular carcinoma and low levels of hepatitis B virus DNA are at risk of hepatitis B virus reactivation following resection, and that perioperative entecavir therapy can safely and effectively reduce this risk. Such therapy also appears to improve liver function and shorten hospitalization.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.